GB Sciences Names Business and Public Policy Expert as Special Advisor to the CEO

LAS VEGAS, Oct. 1, 2014 (GLOBE NEWSWIRE) -- GrowBLOX Sciences, Inc., a.k.a. GB Sciences (OTCQB:GBLX), a cannabinoid therapy research and development firm, has appointed Peter Emerson to serve as the senior advisor to CEO Craig Ellins. In this role, Emerson will work closely with Ellins on a wide range of policy issues primarily to ensure that treatments are uniform in purity, consistency, and potency, just like any other medicine.

"We have the science, the technology, and the right team to elevate cannabinoid therapies to precisely target debilitating medical conditions," said Ellins. "Peter Emerson will facilitate our expansion so that we are able to help patients across the country."

For over forty years, Emerson has helped shape public policy while serving as a senior executive in the US government and during his work with national and international clients. At GB Sciences he will draw upon his experience spearheading strategic communications, marketing, public relations, and advertising initiatives for individuals, corporations, and nonprofit organizations.

"I could not be more pleased to join a company that is seeking to provide evidence-based and medically sound cannabinoid therapies to those afflicted with such wide-ranging chronic conditions as Parkinson's, epilepsy, and pain," said Emerson.

Emerson stays active in both the private sector and academia. In addition to his business pursuits, Emerson serves as Associate for Public Policy at Cambridge Health Alliance's Division on Addiction, a teaching affiliate of Harvard Medical School, and as Chairman of the Task Force on College Gambling Policies.

He also serves as a member of the Board of Directors of the Southern African Enterprise Development Fund, a one-hundred-million-dollar fund created by President Clinton at the urging of Nelson Mandela to foster economic growth and promote the creation of jobs in the Southern African region.

Emerson has contributed op-ed pieces to the New York Times, the Wall Street Journal, and the Boston Globe, as well as postings to the Huffington Post.

He graduated magna cum laude from New York University with a BA and from Harvard Kennedy School of Government with an MPA.

To learn more about GB Sciences, Inc., go to

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc.—aka GB Sciences (OTCQB:GBLX)—is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabinoid therapies that are effective in targeting and treating a variety of medical conditions. The company's pioneering technology, proven processes, and perennial clinical research and development loop enable in-state entities the ability to bring relief to patients in their communities.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Media and Investor Relations Contact: Stephen Hart Hayden IR 917-658-7878Source:GrowBlox Sciences Inc